British Journal of Haematology | 2021
High diagnostic yield of splenic core biopsy in patients with pyrexia of unknown origin
Abstract
immunodeficiency. European J Haematol. 2018;101:48–56. 8. Casulo C, Maragulia J. Zelenetz AD. Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections. Clinical Lymphoma Myeloma and Leukemia. 2013;13(2):106–11. 9. Compagno N, Cinetto F, Semenzato G, Agostini C. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. Haematologica. 2014;99(6):1101–6. 10. G€ unther G, Dreger B. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections. Microbiol Immunol. 2013;57:527–35. 11. Reiser M, Borte M, Huscher D, Baumann U, Pittrow D, Sommer C, et al. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study. European J Haematol. 2017;99:169–77. 12. Smith D, Du Rand IA, Addy C, Collyns T, Hart S, Mitchelmore P, et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. BMJ Open Respirat Res. 2020;7:e000489. 13. Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency, causes, diagnosis, and management. Front Immunology. 2019;10 (33). 14. Duraisingham SS, Buckland M, Dempster J, Lorenzo L, Grigoriadou S, Longhurst HJ. Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement. PLoS One. 2014;9:e100324. 15. Pleyer C, Sun C, Desai S, Ahn IE, Tian X, Nierman P, et al. Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors. Leukemia Lymphoma. 2020;1–8.